Importantly, newly emerging virus variants have the potential to evade the immune response, thereby affecting the efficacy of specific therapies and underlining the importance of new treatment strategies. The researchers compared mice treated with TriSb92 before and after exposure to SARS-CoV-2. Detection of the alpha (B.1.1.7) variant was based on single nucleotide polymorphism analysis for SARS-CoV-2 spike gene mutation N501Y and deletion H69/V70. Absolute changes in viral copy numbers (log10 cp/mL) from baseline (day 1) over time based on the ORF 1a/b gene (ITT analysis set). Thus, a nitric oxide nasal spray was shown to reduce the viral load in adult patients with mild COVID-19 infection, and an accelerated SARS-CoV-2 clearance compared to placebo was demonstrated18. P eople who receive a Covid booster dose in the UK next month will be among the first in the world to receive Moderna's dual-variant vaccine, which protects against two strains of the virus.But . https://doi.org/10.1056/NEJMc2027040 (2021). Therefore, during the treatment phase, patients were required to document the severity of their COVID-19 related symptoms in an electronic diary on a daily basis. To obtain ICE-COVID, will investigate whether Dual Defence can either prevent Covid-19 infection or reduce . 83, 237279. Those parameters were based on the COVID-19 symptoms published by the Robert Koch Institute (https://www.rki.de) at the time of the study. In a study funded by NIAID, researchers are using mice to look for genes that account for different COVID-19 symptoms. Our study population was characterized by an initial mean viral load of log10 6.851.31cp/mL, which was higher than more recently reported SARS-CoV-2 viral load values26. Ralph Msges. Wiesmller (health authorities Cologne, Germany) for his support regarding regulatory issues, PD Dr. E. Raskopf for editorial assistance, and H. Papp for her assistance in PCR control experiments. Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385. In the meantime, to ensure continued support, we are displaying the site without styles Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. Asthma Allergy Immunol. A research study at Swansea University is examining the efficacy of Boots Dual Defence - a 5.99 nasal spray containing seaweed - in preventing people becoming ill with Covid and reducing the . The first administration of the nasal spray was carried out in the presence of the investigator; products were subsequently self-administered for 11days (treatment phase). Of note, pharmacometric analyses of our data indicate that more frequent applications of the nasal spray may be more appropriate for efficient treatment35. Google Scholar. Watts, A. M., Cripps, A. W., West, N. P. & Cox, A. J. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. On day 16, an on-site visit (V8) for female patients was conducted to perform a urine pregnancy test and to assess the safety of the therapy. Three-group comparisons were analysed with KruskalWallis test. Lancet Infect. Comirnaty is FDA-approved as a 2-dose series for the prevention of COVID-19 in individuals 12 years of age and older. N.W. The nasal spray, which contains carragelose, a patented version of iota-carrageenan (a form of seaweed), has already been proven to help shorten the duration and severity of cold and flu-like. What scientists say. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The independent 25 variable was the nasal carriage of Bacillus species. Following sampling, swabs were placed into 3mL Virus Transport Medium (VTM, Biocomma) and delivered to the laboratory as quickly as possible. The researchers first tried one dose a day for seven days, starting a day before SARS-CoV-2 infection. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Konrat, R. et al. 1). and B.S. Lancet Respir. drafted the manuscript. Only one of the 20 mice given saline survived. 147, 400401. By submitting a comment you agree to abide by our Terms and Community Guidelines. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: A randomized clinical trial. Elife 10, e69302. 24 COVID-19 status classified as negative, asymptomatic, mild, or severe. Get the most important science stories of the day, free in your inbox. https://doi.org/10.1080/14787210.2021.1908127 (2021). PubMed The Ct<25 group consisted of 19 patients in the 0.1% azelastine group, 21 patients in the 0.02% azelastine group and of 17 patients in the placebo group (Fig. 62, 50937, Cologne, Germany, You can also search for this author in Following translocation from nucleus to the endoplasmic reticulum (ER), the sigma-1 receptor (among other factors) plays a role in viral replication. The surface of SARS-CoV-2, the virus that causes COVID-19, is covered with spike proteins. The study, published March 28 in the journal Nature, employed experimental mice engineered with human . At the end of the treatment, 48.2% of the patients of the 0.1% azelastine group showed no detection of the ORF 1a/b gene, whereas only 23.1% of patients of the placebo group showed negative PCR results (supplementary Table S4). Comparable numbers of adverse events occurred in all treatment groups with no safety concerns. The overall AUC of the Azelastine 0.1% group (red area) was significantly greater than that of placebo (green area), p=0.007. Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus. 8, 701709. The independent 25 variable was the nasal carriage of Bacillus species. Google Scholar. J. Moreover, this group showed that azelastine has the potential to inhibit SARS-CoV-2 cell entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and to inhibit intracellular virus replication through binding to the sigma-1 receptor6. Anna R. Mkel, PhD, senior scientist, Department of Virology, University of Helsinki, Finland. Researchers began to work on compounds that stifle TMPRSS2s ability to interact with the viral protein. Whether the current data can be extrapolated to other SARS-CoV-2 variants needs to be investigated. Studies into Xlear's antiviral effects on SARS . . PM, MF, DG, CS and BS are employed at URSAPHARM Arzneimittel GmbH. To evaluate the total load during the study, AUC was calculated using a linear equation. Patients of the current trial were eligible upon positive PCR test results, and if enrolled no later than 48h after swab sampling. Assignment of the treatment with the investigational medicinal product in the different doses vs. placebo to each treatment number was performed in a centrally conducted, computer-generated 1:1:1 randomization procedure. With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. Antiviral efficacy was observed at an EC50 of~6M, which is an approximately 400-fold lower concentration compared to commercially available azelastine nasal sprays. Postdoctoral fellowship in vascular biology at UT Southwestern, studying the endothelial basis of cardiometabolic disease. Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml 20.00 Save 3.96 Worth 23.96 when bought separately 1486004 Maximum quantity reached Add to basket Add to favourites Collect 80 Boots Advantage Card points with this purchase Product details In this bundle: JAMA 325, 632644. 2 and supplementary Table S2). Chem. 76, 469475. Slider with three articles shown per slide. Investigators assessed patients status throughout the trial including safety follow-ups (days 16 and 60). and JavaScript. Nat. EudraCT number: 2020-005544-34. As a sensitivity analysis based on the SARS-CoV-2 E gene PCR tended to show overall the same effects, PCR results of the E gene are shown in the supplementary material (supplementary Table S3 and S4). Since viral levels during early infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) tend to be highest in the nose and nasopharynx1, a nasal spray with an active substance inhibiting virus entry and replication may stop or delay the progression of the disease to the lower respiratory system and reduce the transmission to uninfected individuals. Nature 581, 465469. The WHO clinical progression scale progressively decreased in all treatment groups during the study. China and India approve nasal COVID vaccines are they a game changer? 62, 50937, Cologne, Germany, German Center for Infection Research (DZIF) Location Bonn-Cologne, Kerpener Str. Now, researchers at Swansea University will test Boots' Dual Defence Nasal Spray, which costs 5.99 for 20ml, against Covid-19. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients. H.G., M.S., and F.K. But the spike protein may mutate to evade immune response. However, examples of prolonged nasal positivity have also been reported, and many factors are known to have an influence on the individual viral load and clearance27. 15, 75297536. Associate Professor Peter Friedland, from UWA's Medical School, was lead author of the study In vivo . More information about the results of the study, which was funded in part by NIAID. 17(2), 19. It would be desirable to use a validated, COVID-19 specific questionnaire in future studies, and first attempts for its development are promising32. R.M., S.M.S., S.A. and P.M. designed the study protocol. Gottlieb, R. L. et al. 48.9% (n=44) of the safety analysis set was male, and the average age was 35.6712.94years. The investigators judged the efficacy as good or very good in 74.1% (0.1% azelastine treatment), 82.1% (0.02% azelastine treatment) and 73.1% (placebo treatment) of treated patients. Med. The primary endpoint of the CARVIN study was the assessment of virus load kinetics of SARS-CoV-2 by determining the presence and amount of viral carriage via PCR. Lett. Future studies will help understanding the impact of azelastine hydrochloride in treating SARS-CoV-2 infected patients. Sci Rep 13, 6839 (2023). One misinformed. contracts here. The dual-target RT-PCR independently targets the ORF1a/b and the sarbecovirus E genes, and assays were considered positive if at least one target returned a positive result (Ct values reflecting an inverse relationship with viral load). C.A. Categorical data were described by absolute frequencies and percentage of valid cases. Multinomial regression analysis was done to 26 determine the association between nasal carriage of Bacillus and COVID-19 severity after 27 adjusting for age, sex, and co-morbidity status. By Dr. Ramya Dwivedi, Ph.D. Jul 19 2021. Nasal sprays may be a promising first line of defense against SARS-CoV-2 infection. Of note, the decrease of viral load on day 4 was significantly greater in the 0.1% azelastine group (decrease by log10 1.901.03) compared to placebo (decrease by log10 1.050.70).